Insmed Incorporated (NASDAQ:INSM) Receives Average Rating of “Buy” from Brokerages

Insmed Incorporated (NASDAQ:INSM) has been given a consensus recommendation of “Buy” by the sixteen analysts that are presently covering the firm, MarketBeat.com reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $91.60.

Several research analysts recently weighed in on INSM shares. Stifel Nicolaus cut their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Royal Bank of Canada started coverage on shares of Insmed in a report on Tuesday, February 25th. They set an “outperform” rating and a $100.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Wells Fargo & Company boosted their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th.

Insmed Stock Up 1.2 %

Insmed stock opened at $77.21 on Wednesday. Insmed has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The stock has a market cap of $13.97 billion, a PE ratio of -13.81 and a beta of 1.11. The firm’s 50-day simple moving average is $75.32 and its 200 day simple moving average is $73.81. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Research analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity

In other news, insider Martina M.D. Flammer sold 6,172 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.64, for a total value of $392,786.08. Following the sale, the insider now owns 101,549 shares of the company’s stock, valued at $6,462,578.36. The trade was a 5.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the sale, the chief executive officer now directly owns 384,960 shares in the company, valued at $26,885,606.40. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 532,207 shares of company stock valued at $41,400,465 over the last quarter. Company insiders own 4.60% of the company’s stock.

Institutional Trading of Insmed

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jennison Associates LLC increased its holdings in Insmed by 0.6% during the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after acquiring an additional 4,560 shares during the period. Capital CS Group LLC bought a new stake in Insmed during the 4th quarter worth approximately $586,000. Orion Portfolio Solutions LLC increased its holdings in Insmed by 48.5% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after acquiring an additional 9,170 shares during the period. Ally Bridge Group NY LLC increased its holdings in Insmed by 16.9% during the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after acquiring an additional 21,833 shares during the period. Finally, TimesSquare Capital Management LLC bought a new stake in Insmed during the 3rd quarter worth approximately $35,322,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.